慢性肾功能衰竭合并肾性贫血临床治疗

Clinical Treatment of Chronic Renal Failure With Renal Anemia

目的对于慢性肾功能衰竭合并肾性贫血患者采取肾康注射液联合重组人促红细胞生成素进行治疗的具体方法以及治疗效果进行分析。方法选取2018年1月-2019年1月慢性肾功能衰竭合并肾性贫血患者资料40例施行分析,所选40例慢性肾功能衰竭合并肾性贫血患者通过随机法进行分组,其中20例慢性肾功能衰竭合并肾性贫血患者接受皮下注射重组人促红细胞生成素进行治疗作为对照组,剩余20例慢性肾功能衰竭合并肾性贫血患者接受肾康注射液联合重组人促红细胞生成素进行治疗作为研究组,对比两组慢性肾功能衰竭合并肾性贫血患者的治疗效果。结果两组慢性肾功能衰竭合并肾性贫血患者接受各自治疗措施之后的临床总体有效率对比差异明显;两组慢性肾功能衰竭合并肾性贫血患者产生不良反应几率对比差异明显。结论临床中针对慢性肾功能衰竭合并肾性贫血患者,为其提供肾康注射液联合重组人促红细胞生成素进行治疗效果理想,应该给予大力的推广与应用。

Objective To analyze the specific treatment methods and therapeutic effects of shenkang injection combined with recombinant human erythropoietin in patients with chronic renal failure complicated with renal anemia. Methods From January 2018 to January 2019, Data of 40 patients with chronic renal failure complicated with renal anemia were selected for analysis, selected 40 patients with chronic renal failure with renal anemia by random grouping, including 20 cases of chronic renal failure with renal anemia patients received subcutaneous injection of recombinant human erythropoietin for treatment as control group, the remaining 20 cases of chronic renal failure with renal anemia patients accepted renal injection joint treatment with recombinant human erythropoietin and shenkang injection as the study group, compared to two groups of patients with chronic renal failure with renal anemia treatment effect. Results There were significant differences in overall clinical response rates between the two groups of patients with chronic renal failure complicated with renal anemia. The incidence of adverse reactions in patients with chronic renal failure complicated with renal anemia was significantly different between the two groups. Conclusion Shenkang injection combined with recombinant human erythropoietin is effective in the treatment of chronic renal failure patients with renal anemia.